Bayer taps a second partner to develop Vitrakvi's companion diagnostic

Six months into Vitrakvi larotrectinib's approval as a tissue-agnostic therapy, Bayer has added a second co-development partnership for the NTRK inhibitor's still-needed companion diagnostic, this time with Roche's Foundation Medicine unit.

In April 2018, Vitrakvi's

Read the full 344 word article

User Sign In